We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...

We recently compiled a list of the 7 Blue Chip Stocks with Low PE Ratios. In this article, we are going to take a look at ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...

Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

On Wednesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $110.42 which represents a decrease of $-1.11 or -1.00% from the prior close of $111.53. The stock opened at $111 and touched ...

Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...

Mestag Therapeutics has been working to change how fibroblasts are activated and how they expand. Now, Merck & Co. | Mestag ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

In this article, we will look at where Merck & Co. Inc. (NYSE:MRK) ranks among the most undervalued quality stocks to buy according to analysts. Are More Rate Cuts Necessary to Maintain The ...

On Oct. 1 and 2, the American Chemical Society held its 21st annual Pharma Leaders Conference, hosted this year at the Merck & Co. campus in Rahway, New Jersey. Leaders in medicinal chemistry from ...